Investigation of the pharmacodynamics and pharmacokinetics of vancomyci n during continuous veno-venous hemofiltration therapy in a patient with renal failure

葛卫红,顾勤,贺玲,陈志一

DOI: https://doi.org/10.3321/j.issn:1001-2494.2001.11.012

2001-01-01

Abstract:OBJECTIVE: To investigate the pharmacodynamic and pharmacokinetic properties of vancomycin during continuous veno-venous hemofiltration (CVVH) therapy in a patient with renal failure. METHODS: A patient with kidney failure received 0.5 g vancomycin infusion during CVVH therapy. On 3rd day and 16th day during the therapy, blood samples were collected after the dosing. The serum concentrations of vancomycin were measured by TDx. The pharmacokinetic parameters were calculated using PKBPN1 software. The pharmacodynamic targets of vancomycin were observed. RESULTS: The pharmacokinetics of vancomycin during CVVH was fitted well with open two-compartment model. On the 3rd day of CVVH therapy, the pharmacokinetic parameters were: t1/2α0.41 h, t1/2β5.75 h, Vc 21.92 L, cmax 22.81 μg·mL-1, cmin 5.82 μg·mL-1, CL 3.49 L and Vss 28.32 L, respectively. On the 16th day, the PK parameters were: t1/2α 0.61 h, t1/2β 33.23 h, Vc 12.92 L, cmax 38.70 μg·mL-1,cmin 16.50 μg·mL-1, CL 0.367 L and Vss 17.69 L, respectively. The pharmacodynamic targets of vancomycin were body temperature, white blood count and bacteria in phlegm. CONCLUSION: It demonstrated that the pharmacokinetic properties of vancomycin changed with time during CVVH treatment. Therefore, the monitoring of blood drug concentration during the therapy was necessary and the dosage regiment should be adjusted accordingly.